E 7011
Alternative Names: E-7011Latest Information Update: 28 Jul 2024
At a glance
- Originator Eisai Co Ltd
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Angiogenesis inhibitors; Notch receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)
- 08 Apr 2022 Pharmacodynamics data from preclinical trial in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 22 Jun 2020 Preclinical trials in Cancer in Japan (Parenteral) before June 2020